Advances in the assessment of minimal residual disease in mantle cell lymphoma

Research output: Contribution to journalReview articlepeer-review

Abstract

The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in determining the prognosis. Flow cytometry and polymerase chain reaction-based testing are most commonly used methods in practice; however, these methods are not sensitive enough to detect the dynamic changes that underline lymphoma progression. Newer methods using next-generation sequencing, such as ClonoSeq, are being incorporated in clinical trials. Other techniques under evolution include CAPP-seq and anchored multiplex polymerase chain reaction-based methods. This review article aims to provide a comprehensive update on the status of minimal residual disease detection and its prognostic effect in mantle cell patients. The role of circulating tumor DNA-based minimal residual disease detection in lymphomas is also discussed.

Original languageEnglish (US)
Pages (from-to)127
Number of pages1
JournalJournal of hematology & oncology
Volume13
Issue number1
DOIs
StatePublished - Sep 24 2020

Keywords

  • Liquid biopsy
  • Mantle cell lymphoma
  • Minimal residual disease
  • Next-generation sequencing
  • ctDNA

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Advances in the assessment of minimal residual disease in mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this